<DOC>
	<DOCNO>NCT01146340</DOCNO>
	<brief_summary>The purpose study determine safety efficacy short course radiotherapy ( 40 Gy / 5 fraction / 29 day ) treatment low- intermediate-risk prostate cancer .</brief_summary>
	<brief_title>Safety Efficacy Study Dose-escalated Hypofractionated Radiotherapy For Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Men &gt; 18 year Histologically confirm prostate adenocarcinoma Low lowintermediate risk prostate cancer , define Clinical stage T12b , Gleason Score &lt; =6 , PSA &lt; 15 ng/mL , OR Clinical stage T12b , Gleason Score 7 , PSA &lt; =10 ng/mL Prior pelvic radiotherapy Anticoagulation medication ( unsafe discontinue gold seed insertion ) Diagnosis bleed diathesis Presence hip prosthesis Pelvic girth &gt; 40cm Large prostate ( &gt; 90cm3 ) imaging Severe low urinary tract symptom ( International Prostate Symptom Score &gt; 19 nocturia &gt; 3 )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Prostatic Neoplasms</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Hypofractionation</keyword>
	<keyword>Low Intermediate Risk Prostate Cancer</keyword>
</DOC>